Bio-Rad Laboratories, Inc. (BIO) Total Return CAGR:31.77%(TTM)
The total return cagr for Bio-Rad Laboratories, Inc. (BIO) is +31.77% over the latest trailing 12-month period. The comparable SPY value is +24.32%. Year-to-date total return is -1.92%. Total return includes price appreciation and reinvested dividends.
The total return cagr for Bio-Rad Laboratories, Inc. (BIO) stock is 31.77% over the past 12 months. The 3 year average growth rate is -6.28% and the 5 year cagr is -12.56%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of Bio-Rad Laboratories, Inc.'s investment performance.
BIO Total Return CAGR Chart
Bio-Rad Laboratories, Inc. (BIO)
BIO Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 1683.28 | 1650.94 | -32.33 | -1.92% | -1.92% |
| 2025 | 1825.06 | 1683.28 | -141.78 | -7.77% | -7.77% |
| 2024 | 1793.83 | 1825.06 | +31.22 | +1.74% | +1.74% |
| 2023 | 2336.06 | 1793.83 | -542.22 | -23.21% | -23.21% |
| 2022 | 4197.61 | 2336.06 | -1861.56 | -44.35% | -44.35% |
| 2021 | 3238.56 | 4197.61 | +959.06 | +29.61% | +29.61% |
| 2020 | 2055.72 | 3238.56 | +1182.83 | +57.54% | +57.54% |
| 2019 | 1290.11 | 2055.72 | +765.61 | +59.34% | +59.34% |
| 2018 | 1325.94 | 1290.11 | -35.83 | -2.70% | -2.70% |
| 2017 | 1012.67 | 1325.94 | +313.28 | +30.94% | +30.94% |
| 2016 | 770.33 | 1012.67 | +242.33 | +31.46% | +31.46% |
| 2015 | 669.78 | 770.33 | +100.56 | +15.01% | +15.01% |
| 2014 | 686.72 | 669.78 | -16.94 | -2.47% | -2.47% |
| 2013 | 583.61 | 686.72 | +103.11 | +17.67% | +17.67% |
| 2012 | 533.56 | 583.61 | +50.06 | +9.38% | +9.38% |
| 2011 | 576.94 | 533.56 | -43.39 | -7.52% | -7.52% |
| 2010 | 535.89 | 576.94 | +41.06 | +7.66% | +7.66% |
| 2009 | 418.39 | 535.89 | +117.50 | +28.08% | +28.08% |
| 2008 | 575.67 | 418.39 | -157.28 | -27.32% | -27.32% |
| 2007 | 458.44 | 575.67 | +117.22 | +25.57% | +25.57% |
| 2006 | 363.56 | 458.44 | +94.89 | +26.10% | +26.10% |
| 2005 | 318.72 | 363.56 | +44.83 | +14.07% | +14.07% |
| 2004 | 320.39 | 318.72 | -1.67 | -0.52% | -0.52% |
| 2003 | 215.00 | 320.39 | +105.39 | +49.02% | +49.02% |
| 2002 | 175.83 | 215.00 | +39.17 | +22.27% | +22.27% |
| 2001 | 88.33 | 175.83 | +87.50 | +99.06% | +99.06% |
| 2000 | 64.93 | 88.33 | +23.40 | +36.04% | +36.04% |
| 1999 | 58.33 | 64.93 | +6.60 | +11.31% | +11.31% |
| 1998 | 72.57 | 58.33 | -14.24 | -19.62% | -19.62% |
| 1997 | 83.33 | 72.57 | -10.76 | -12.92% | -12.92% |
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz